OPSYNVI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Opsynvi, and what generic alternatives are available?
Opsynvi is a drug marketed by Actelion and is included in one NDA.
The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the macitentan; tadalafil profile page.
Summary for OPSYNVI
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OPSYNVI |
What excipients (inactive ingredients) are in OPSYNVI? | OPSYNVI excipients list |
DailyMed Link: | OPSYNVI at DailyMed |
Pharmacology for OPSYNVI
Drug Class | Endothelin Receptor Antagonist Phosphodiesterase 5 Inhibitor |
Mechanism of Action | Endothelin Receptor Antagonists Phosphodiesterase 5 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for OPSYNVI
US Patents and Regulatory Information for OPSYNVI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-001 | Mar 22, 2024 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-002 | Mar 22, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |